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Abstract
Lung transplantation is a radical but life-saving treatment option for patients with end-stage lung diseases, such as
idiopathic pulmonary fibrosis (IPF) and scleroderma. In light of the proposed association and controversy linking
gastroesophageal reflux disease (GERD) to IPF and lung transplant outcome, the American Gastroenterological
Association convened during the DDW inWashington inMay 2015 a multidisciplinary group of experts in the field
ofGERD and lung transplantation tomake considerations about the care of these patients based on available data and
subsequent expert panel discussion at this symposium. The following topics were discussed: (1) pathophysiology of
GERD-induced pulmonary symptoms, (2) GERD evaluation before and after lung transplantation, (3) outcome of
lung transplantation for IPF and scleroderma, and (4) role of laparoscopic fundoplication before or after lung
transplantation.
Introduction
Lung transplantation is a radical but life-savingtreatment option for patients with end-stage lung dis-
eases (ESLDs), such as idiopathic pulmonary fibrosis (IPF)
and scleroderma.
Based on the most recent data from the U.S. Department of
Health and Human Services, nearly 30,000 primary lung
transplants have been performed since 1988.1 Even though
the overall graft survival has increased over the years, as of
2015, the median 1-, 3-, and 5-year graft survival was 83.1%,
62.1%, and 46.2%,1 respectively, still lower than that of the
kidneys and livers.
The most common cause of chronic allograft dysfunction is
known as obliterative bronchiolitis, a process of fibrosis that
starts in the small bronchioles of the transplanted lung. The
clinical correlate is the bronchiolitis obliterans syndrome
(BOS), characterized by a progressive deterioration of lung
function asmeasured by the forced 1-second expiratory volume
(FEV1). Although the pathophysiology of BOS is unknown,
theories of BOS and rejection after transplantation have
centered on the combined interaction of immunologic
and nonimmune factors. Nonimmune factors, such as gastro-
esophageal reflux disease (GERD), have been postulated to
induce rejection by triggering a nonallogenic injury to the
transplanted lungs by aspiration of gastroesophageal contents.2
Similarly, before transplantation, the presence of GERD-
induced aspiration has been linked to pulmonary failure, par-
ticularly in patients with IPF.3 Therefore, GERD is thought to
play a significant role in the decline in lung function before
transplantation and the rejection after lung transplantation,
likely by causing aspiration-mediated lung injury.
In light of the proposed association and controversy link-
ing GERD to IPF and lung transplant outcome, the American
Gastroenterological Association convened during the DDW
in Washington in May 2015 a multidisciplinary group of
experts in the field of GERD and lung transplantation to make
considerations for the care of these patients based on avail-
able data and subsequent expert panel discussion at this
symposium. The following topics were discussed: (1) path-
ophysiology of GERD-induced pulmonary symptoms, (2)
GERD evaluation before and after lung transplantation, (3)
1Pritzker School of Medicine, University of Chicago, Chicago, Illinois.
2Mayo Clinic Arizona, Scottsdale, Arizona.
3Northwestern University, Chicago, Illinois.
4University of South Florida, Tampa, Florida.
5Brigham and Women’s Hospital, VA Boston, Boston, Massachusetts.
6Vanderbilt University, Nashville, Tennessee.
Symposium of GERD and Lung Disorders, American Gastroenterological Association, DDW, Washington, May 18, 2015.
*University of North Carolina, Chapel Hill, NC.
JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES
Volume 26, Number 7, 2016
ª Mary Ann Liebert, Inc.
DOI: 10.1089/lap.2016.0170
501
outcome of lung transplantation for IPF and scleroderma, and
(4) role of laparoscopic fundoplication before or after lung
transplantation.
Pathophysiology of GERD and Its Importance
in Patients with ESLD and Lung Transplant Patients
Traditionally, the presence and severity of GERD were
related to the incompetence of the lower esophageal sphinc-
ter, the abnormal esophageal peristalsis, and the presence and
size of hiatal hernia.4 Today, emphasis is also placed on
the role of mixed gastroesophageal reflux5 and on the trans-
diaphragmatic pressure gradient6 as both have important
therapeutic implications.
The importance of the mixed gastroesophageal reflux is
evident when one compares the number of reflux episodes on
and off proton pump inhibitors (PPI) therapy using multi-
channel intraluminal impedance and pHmonitoring, a finding
that has significant implications on the choice of treatment for
patients with GERD and aspiration. For instance, Tamhankar
et al. showed that PPIs just change the pH of the gastric re-
fluxate from acidic to weakly acidic or alkaline but do not
change the occurrence and the number of reflux episodes.5
The authors concluded, ‘‘PPI treatment, while altering the pH
of the gastric juice, does not correct the defects in the gastro-
esophageal barrier and consequently does not eliminate the
presence and frequency of refluxed gastric contents.’’ Hence,
if one considers aspiration the central focus of lung deterio-
ration before and after lung transplant, it is clear that treatment
with PPI is not as effective as a fundoplication, which is able
to stop any type of reflux events regardless of their pH. In
addition, emphasis has been placed on the role of the trans-
diaphragmatic pressure gradient in causing GERD. A study
from the University of California San Francisco showed that
for a 5-point increase in the body mass index, there was a
3-point rise in the DeMeester score.5 This is particularly
relevant in obese patients in whom there is an increased
gradient because of a higher abdominal pressure and a more
negative intrathoracic pressure.7
Evaluation of Patients with ESLD Before
and After Lung Transplant
Testing for esophageal motility and GERD is very im-
portant in the management of patients with ESLD and after
lung transplantation.
The assessment of esophageal motility relied on conven-
tional manometry for many years. Nowadays, a more com-
mon approach is to use high-resolution manometry (HRM),
which incorporates a large number of closely spaced pressure
sensors and provides spatiotemporal plots of esophageal
pressure changes, leading to higher diagnostic accuracy.
Esophageal motor disorders are common in patients with
advanced lung disease. A study that assessed 30 lung trans-
plant candidates with HRM found intermittent or frequent
failed peristalsis in 20 (66%) of them.8 More recently, in 73
patients being evaluated for lung transplant, HRM revealed a
hypotensive lower esophageal sphincter (LES) in 23% and
hypomotility of the esophageal body in 36%.1 While esoph-
ageal manometry does not provide a diagnosis of GERD, it is
mandatory for the following reasons: (1) proper positioning
of the pH probe, (2) before antireflux surgery to rule out
achalasia masquerading as GERD, and (3) to detect severe
impairment or absent peristalsis, particularly in patients with
scleroderma.9 GERD is often suspected when patients com-
plain of typical symptoms, such as heartburn and regurgita-
tion. However, these symptoms have variable sensitivity and
specificity for diagnosing GERD. In addition, patients with
GERD and ESLD are often asymptomatic.10 In a study of
patients awaiting lung transplant, 33% of those who tested
positive for GERD by pH monitoring had no heartburn or
regurgitation.11 Endoscopy can provide a diagnosis of GERD
when erosive esophagitis is detected; however, this finding is
present in only one third of untreated patients,12 and it is even
less common in those treated with a PPI. Thus, at the present
time, the most reliable method for establishing the presence of
pathological gastroesophageal reflux is through ambulatory pH
monitoring or by pH monitoring combined with impedance.
The prevalence of GERD is very high in patients with ad-
vanced pulmonary disease undergoing transplant evaluation.
In a study of 62 patients awaiting lung transplant, 24-hour pH
monitoring was positive for GERD in 58%.1 A positive pH
test before transplant is associated with worse outcomes after
transplant. This was demonstrated in a study of 114 patients in
whom pretransplant GERDwas diagnosed by pHmonitoring.
During follow-up after transplant, allograft function was de-
creased in patients with pretransplant GERD compared to
those without GERD, such that by 18 months, FEV1 was 70%
of predicted in patients with GERD versus 83% among non-
GERD patients.5 Furthermore, survival early after transplant
was significantly lower in the GERD patients. Testing for
GERD with pH monitoring is also useful after transplant. In
60 lung transplant recipients who underwent pHmonitoring 3
months after transplant or at the time of their first acute re-
jection, a multivariate model showed that GERD was asso-
ciatedwith a significantly increased rate of acute rejection and
with earlier as well as multiple episodes and rejection.12
There are limited data regarding the utility of pH–impedance
monitoring in lung transplant patients. The main advantage of
pH–impedance monitoring is the ability to detect reflux with
a pH above 4, which is highly relevant in lung transplant pa-
tients on treatment with a PPI because nonacidic reflux may
be harmful as suggested by lower allograft function in GERD
patients treated with PPI compared to those who undergo early
fundoplication.13 This may be explained by reflux of bile and
pepsin even when pH is above 4.0, as shown by a study of 24
lung transplant recipients evaluated by impedance–pH moni-
toring and bronchoalveolar lavage fluid (BALF) analysis 1 year
after transplant, revealing an association between increased noc-
turnal weakly acidic reflux and the presence of bile in BALF.14
A more accurate way to document reflux and aspiration of
gastric contents in patients with pulmonary disease is by mea-
surement of pepsin or bile acids in BALF obtained during
bronchoscopy. In a study of 105 lung transplant recipients, the
BALF concentrations of pepsin were significantly higher in the
29 patients who developed BOS compared to those without
BOS.15 Similarly, bile acid measurement in BALF in 120
transplant recipients showed that freedom from BOS was sig-
nificantly shortened in patientswith elevatedBALFbile acids.16
Evidence that GERD Plays a Role in Causing
or Worsening Lung Diseases, such as IPF
GERD is highly prevalent and often silent in patients with
IPF.2 Raghu et al. reported a prevalence of abnormal reflux
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by 24-hour pH monitoring of 87% in 65 patients with IPF,
with a prevalence of proximal reflux of 63%.3 Similarly,
Sweet et al. evaluated 109 ESLD patients awaiting lung
transplantation and found that distal reflux was present in
68% of patients and proximal reflux was present in 37% of
patients.10 Moreover, Allaix et al., in a study of 22 GERD and
IPF patients who were compared to 80 controls with GERD
only, showed that in patients with GERD and IPF the prox-
imal esophageal acid exposure was higher and that the supine
acid clearance was slower compared with those with GERD
only.17 The high prevalence of GERD and proximal reflux
suggests that these patients are more susceptible to aspiration,
the postulated ultimate mechanism of chronic lung injury. In
addition, because in lung transplant candidates reflux is often
silent, a screening protocol for GERD should always include
manometry and pH monitoring. The presence of pepsin or
bile acids should be systematically sought in the BALF as a
proof of aspiration of gastric contents. Similarly, these tests
should also be routinely performed in any patient after lung
transplantation even if abnormal reflux was not present at the
time of the pretransplant evaluation. D’Ovidio et al. showed
that in patients after lung transplantation, bile was commonly
detected in the BALF.18 In addition, they showed that free-
dom from BOS was reduced in patients with abnormal
esophageal reflux or when bile acids were present in their
BALF. They concluded that reflux-mediated aspiration was a
risk factor for the development of BOS after transplant and
that aspiration of bile acids was associated with impaired
allograft innate immunity.8
Evidence that Antireflux Surgery in Patients
with IPF Can Block the Progression of the Disease
If GERD is highly prevalent and often silent in patients with
ESLD before transplantation, and if pretransplant GERD is
associated with worse early allograft function and survival,19
then onemay argue that GERD should be controlled before the
deterioration, leading to lung transplantation. Linden et al.
compared the outcome of 14 patients with GERD and IPF on
the lung transplant list who underwent laparoscopic antireflux
surgery (LARS)with that of a control group of 31 patients with
GERD and IPF on the transplant list who did not undergo
LARS. They found that in patients with IPF who underwent
LARS, there was stabilization of oxygen requirements, whereas
controls had a significant deterioration in oxygen require-
ments.20 Hoppo et al. evaluated 19 patients with GERD and
ESLD before lung transplant and found that 1 year after
LARS the FEV1 improved in 85% of them and that episodes
of pneumonia and acute rejection stabilized.21 Longer sur-
vival in patients with IPF taking PPI or after Nissen fundo-
plication was also documented by Lee et al.22 To further
clarify the effect of reflux control in patients with GERD and
IPF, the National Institutes of Health is sponsoring a phase II
multicenter study of laparoscopic fundoplication for the
treatment of GERD in IPF patients (University of California
San Francisco; University of Washington, Seattle; University
of Michigan; University of Wisconsin, Madison; and Uni-
versity of Chicago). This study aims to determine if by
blocking reflux the natural history of the disease can be
changed, and specifically, it aims to determine the impact of
LARS on the decline of forced vital capacity (FVC) to de-
termine the safety of LARS in patients with IPF.
Evidence that Early Antireflux Surgery in Patients
with GERD After Lung Transplant Can Prevent
BOS or At Least Block Its Progression
Even though BOS is multifactorial, GERD probably
plays a major role, and surgical treatment of GERD with
LARS has been shown to reduce the incidence of BOS and
associated with a delay in the onset or progression of BOS
or even with improvement in lung function. Fisichella
et al. showed that LARS could stop aspiration by provid-
ing a mechanical barrier to reflux. They categorized those
who had aspiration as those who had any pepsin in their
BALF (pepsin was undetectable in the BALF of controls)
and found that lung transplant patients with LARS had
minimal pepsin levels in their BALF.23 Davis et al. studied
128 patients who had esophageal function tests after lung
transplantation.24 Among these, 43 patients underwent
LARS, while the other patients served as controls. At the
time of LARS, 26 patients had BOS, whereas after the
fundoplication, BOS resolved in 13 patients. In addition,
Davis et al. found that 6 months after LARS the FEV1
improved by 24% compared to preoperative values and that
the overall actuarial survival was better when a patient had
no objective evidence of reflux on pH monitoring. Davis
et al. were the first to speculate that an early fundoplication
(within 6 months) may improve lung function and affect the
resolution of BOS.
Cantu et al. built on these findings and investigated if early
fundoplication would prevent BOS and improve survival.
They found that patients who underwent early LARS had
100% freedom from BOS at 1 and 3 years compared with
those with reflux who did not undergo LARS (96% and 60%
at 1 and 3 years, respectively).25 In patients after LARS, the
actuarial survival was 100% at 1 and 3 years compared with
those with reflux and no intervention (92% and 76% at 1 and
3 years, respectively).
Hartwig et al. subsequently showed that early LARSmight
indeed preserve lung allograft function by finding that lung
transplant patients with abnormal reflux who did not undergo
LARS had worse predicted peak and 1-year FEV1 results
compared to those who had LARS.13 Finally, Lo et al. eval-
uated the impact of the timing of LARS (before and after
transplantation) on early allograft injury and found that late
LARS (>6 months after lung transplant) resulted in increased
risk of early allograft injury compared to pretransplant and
early LARS (<6 months).26 These findings support the use of
LARS early after transplantation or even before transplanta-
tion to minimize the impact of reflux-induced aspiration on
allograft injury.
Early fundoplication after lung transplantation, before
worsening lung function, has been shown to be safe. Gasper
et al. showed that 35 operations (15 performed before and
20 after transplantation) were all completed laparoscopically,
and 33 (94%) patients recovered uneventfully (one was
readmitted for urinary tract infection and one died for causes
nonrelated to the transplant).27 The median hospital length of
stay was 2 days. Similarly, Fisichella et al. analyzed the
perioperative morbidity and mortality of 29 consecutive lung
transplant patients and 23 consecutive patients without ESLD
(control group). They showed that the morbidity and mor-
tality of LARS in lung transplant patients and the control
group were equivalent.28
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Scleroderma and Esophageal Dysmotility
in Lung Transplantation: Clinical Implications
and Outcome
Scleroderma is an autoimmune collagen vascular disease
characterized by fibrosis of small arteries and arterioles,
which presents with cutaneous and/or visceral manifesta-
tions. In addition to the skin, the gastrointestinal tract, lung,
kidney, and heart are the most commonly involved organs.
Today, pulmonary disease is the main organ-specific cause of
death in the scleroderma patient population, with 3-year
mortality exceeding 50%.29 The main manifestations of lung
disease are interstitial fibrosis (50% of patients) and pulmo-
nary arterial hypertension (5%–12%).30 Because medical
therapy has limited efficacy in scleroderma lung disease, lung
transplantation is the only definitive treatment option for
patients with scleroderma lung disease. However, given the
concern regarding the impact of concomitant extrapulmo-
nary manifestations of scleroderma—particularly esophageal
dysmotility with gastroesophageal reflux and aspiration—
lung transplantation remains controversial in these patients.
This view, however, has slowly changed over time. A
review of the United Network for Organ Sharing (UNOS)
database in 2005 identified 47 patients who underwent lung
transplant for scleroderma with survival at 1 and 3 years of
68% and 46%, respectively.31 These survival figures were
not significantly different from those seen with contempo-
rary interstitial lung disease (ILD) patients (76% and 59%;
P = .25), indicating that sustained acceptable outcomes were
indeed possible in this patient population. Given the specific
concerns regarding transplantation in the setting of GERD,
Sottile et al. examined the outcome of lung transplants in
patients with documented reflux as defined by a DeMeester
score >14.7.29 In comparison to a matched cohort of IPF
patients, there were no differences in survival at 1 year (83%
versus 91%) and 5 years (76% versus 64%; P = .47). Eso-
phageal dysfunction was not associated with a difference in
BOS or an increased mortality following transplantation.
The ongoing management of gastroesophageal reflux and
aspiration in patients with scleroderma is a critical compo-
nent. Patient should be assessed with esophageal manometry
and pH monitoring. If abnormal reflux is present, antireflux
surgery has been shown to offer benefit in both survival and
reduced rejection following lung transplantation.25 However,
in the setting of the significant esophageal dysfunction in
scleroderma, fundoplication can aggravate dysphagia, even if
a partial fundoplication is performed.32 Kent et al. proposed
that Roux-en-Y esophagojejunostomy might be a better op-
tion in these patients, offering improved reflux control and
less dysphagia compared to fundoplication.33
In the most recent update of the guidelines for the selec-
tion of transplant candidates, The International Society for
Heart & Lung Transplantation stated, ‘‘carefully selected
candidates with (scleroderma) can undergo successful lung
transplantation.’’34 Ultimately, the decision regarding
transplant candidacy must be made on a case-by-case basis,
taking into consideration the severity of lung disease and the
concomitant comorbidities.
Conclusions
The mechanism by which GERD contributes to the de-
velopment of IPF and BOS and rejection after transplant has
not been well elucidated. Evidence is conflicting because
studies are limited in their size and mostly uncontrolled.
Nevertheless, the evidence available seems to suggest that
GERD should be recognized and treated early in patients with
IPF: the phase II NIH prospective and randomized trial cur-
rently in course might shed definitive light on the role of
GERD in the pathogenesis of this disease. Awareness of the
medical community, from family practitioners to pulmonol-
ogists, that GERDmay play a role in the pathogenesis of lung
diseases and in the rejection process after lung transplant is of
paramount importance.
With the caveat that most of the studies are retrospective
and based on small number of patients, the reader should
realize that guidelines are difficult to be proposed. However,
based on the review of the available literature and the per-
sonal experience of the participants to this symposium, the
following considerations were made:
 Every patient with IPF and scleroderma and ESLD should
be screened for GERD by manometry, pH monitoring,
and possibly by bronchoscopy with analysis of the BALF
for pepsin or bile acids, irrespective of the presence of
symptoms.
 If the presence of GERD and aspiration is established
and the patient is considered a candidate for an operation
under general anesthesia, LARS should be considered.
 Every patient early after lung transplant should be screened
for GERD bymanometry, pHmonitoring, and possibly by
bronchoscopywith analysis of the BALF for pepsin or bile
acids, irrespective of the presence of symptoms.
 If GERD is detected, a fundoplication should be per-
formed as soon as the diagnosis is established and
before the development of BOS.
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